Navigation Links
Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/9/2011

LOS ANGELES, Dec. 9, 2011 /PRNewswire/ -- Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.  These presentations are further detailed below:

Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With ErbB2-positive Breast Cancer

The Phase I/II clinical trial of PB272 given in combination with the chemotherapy drug capecitabine was conducted at numerous locations in the United States, Europe and Asia.  The trial was sponsored by Pfizer and the Phase I results of this trial were previously presented last year.  The Phase II portion of the study, presented at this symposium, enrolled patients with confirmed ErbB2+ (HER2+) metastatic or locally advanced breast cancer, and documented disease progression following prior treatment with trastuzumab and taxane chemotherapy.  Patients were administered PB272 at a dose of 240 mg per day in combination with capecitabine given at a dose of 1,500 mg/m2 (750 mg/m2 twice daily) on Days 1 to 14 of each 21-day cycle.

The results of the study showed that the combination of PB272 and capecitabine had acceptable tolerability.  The most frequently observed severe adverse event in the trial was diarrhea with 26% of the patients experiencing grade 3/4 diarrhea.  The diarrhea was reported to be transient and managed with antidiarrheal agents and dose modifications.  The efficacy results from the trial showed that for the 61 patients in the trial who had not been previously treated with the HER2 targeted agent lapatinib, 7 (11%) patients experienced a complete response, 32 (52%) patients experienced a partial response and 5 (8%) patients experienced stable disease for greater than 6 mo
'/>"/>

SOURCE Puma Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
2. Animal Biotechnology - Technologies, Markets and Companies
3. Puma Biotechnology Announces Completion of Private Placement
4. HUYA Bioscience International Builds Long-Term Relationship with Shenzhen Polytechnic School of Applied Chemistry and Biotechnology
5. Congressman Eric Cantor and Health Diagnostic Laboratory, Inc. Discuss Job Growth at Virginia BioTechnology Research Park
6. Industrial Biotechnology China News 1109 - Annual Subscription
7. Nanobiotechnology: Applications and Global Markets
8. Californias Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation
9. Global Biotechnology Instrumentation Industry
10. Separation Systems for Commercial Biotechnology
11. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 BioMedomics, Inc. ... ultra-sensitive POC diagnostic platforms and novel disease specific POC tests, ... of financing netting a total of $690,000. The investment is ... in the company. This group of private investors has significant ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... naturally occurring antibodies contained in, GAMMAGARD LIQUID ... disease, CHICAGO, April 15 The University ... (NYSE: BAX ) today,announced data from a ... [Immune Globulin Intravenous (Human)] (IGIV),marketed as KIOVIG in ...
... BIRMINGHAM, Ala., and CEDARHURST, N.Y., April 15 ,BioHorizons, ... of Implant Logic Systems, Ltd. ("ILS"), first announced ... as a subsidiary of,BioHorizons. Steve Boggan, CEO of ... offering to include VIP Virtual Implant Placement,planning software ...
... PALO ALTO, Calif., April 15 CV Therapeutics,Inc. ... Capital has agreed to pay,CV Therapeutics up to ... percent of,CV Therapeutics, royalty on North American sales ... on closing,of the transaction and could receive a ...
Cached Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioHorizons Announces the Purchase of Implant Logic Systems 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3
(Date:7/9/2014)... which animals can be found, concern mounts over the ... range for a host mean new territory for its ... of UC Santa Barbara scientists, including parasitologists Ryan Hechinger ... Journal of Biogeography , Hechinger, Kuris and colleagues ... Hosts may actually lose their parasites when the hosts ...
(Date:7/9/2014)... derived from the oils produced by algae may offer ... this goal, optimization of cost effective strategies for large-scale ... needed. Sapphire Energy has developed an innovative solution to ... systems, described in Industrial Biotechnology , a peer-reviewed ... is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... The University of Nottingham are to receive more than 5 ... make rural living in both the UK and India more ... opportunities for small scale energy generation through renewable sources, developing ... of mobile technologies to grow wealth in rural communities. , ...
... landscapes have undergone great change in recent decades, but species ... roe deer, Spanish ibex, red deer and wild boar. ... the effects of changes in land use on the past, ... last few decades there has been an increase in the ...
... serious gastric disorders including stomach cancer may be a step ... chemist. In the first published study of its kind, ... found a carbohydrate-based antigen caused mice to develop antibodies against ... the first jab at a sugar-based vaccine against Helicobacter ...
Cached Biology News:Nottingham researchers help bridge the urban and rural divide in the UK and India 2Nottingham researchers help bridge the urban and rural divide in the UK and India 3Nottingham researchers help bridge the urban and rural divide in the UK and India 4Changes in land use favor the expansion of wild ungulates 2
... Channel Cell Lines ,High Quality, Functionally-Validated, Ion ... well known for having a critical role ... have a key function in pain, CNS ... channels have been investigated in therapeutic areas, ...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
Biology Products: